Isolagen Inc. Completes Injections Of Isolagen Therapy(TM) In Phase II/III Acne Scar Study

Isolagen(TM), Inc. (Amex:
ILE) announced that all injections have been completed in the Phase
II/III Study IT-A-008 investigating Isolagen Therapy(TM) for the treatment
of moderate to severe facial acne scars. Further, approximately half of all
of the study participants have completed the final observation visit.
Isolagen anticipates the acne study will conclude in the first quarter of
2009.



"The second half of 2008 has been very productive for Isolagen as we
continue to deliver on our clinical milestones on time and with positive
results," said Declan Daly, Chief Executive Officer of Isolagen. "We
previously announced positive top-line results from our pivotal Phase III
wrinkle study and positive results from our open label Phase II study of
the full face. We are very excited that our acne program is progressing on
time and we believe the dermatology community will be very interested in
this data early next year because of the unmet need for a minimally
invasive acne scar treatment. Our current priority is to gain additional
funding and secure a strategic partner to help us deliver on the exciting
clinical promise of the Isolagen therapy in all of these areas."



About the Isolagen Process(TM) and Isolagen Therapy(TM)



The Isolagen Process(TM) is an innovative cellular processing system
which creates a natural, living cell therapy. By multiplying a patient's
own collagen-producing cells or fibroblasts into tens of millions of new
cells, a personalized treatment is created which is then returned to the
patient's skin. This treatment, known as the Isolagen Therapy(TM), is
designed to improve skin damage caused by the normal effects of aging, sun
damage, acne and burns.



About Isolagen, Inc.



Isolagen(TM), Inc. (Amex: ILE) is an aesthetic and therapeutic company
committed to developing and commercializing scientific advances and
innovative technologies. The company's technology platform includes the
Isolagen Process(TM), a cell processing system for skin and tissue
rejuvenation which is currently in clinical development for a broad range
of aesthetic and therapeutic applications including wrinkles, acne scars,
burns and periodontal disease. Isolagen also commercializes a
scientifically-advanced line of skincare systems through its majority-owned
subsidiary, Agera(R) Laboratories, Inc. For additional information, please
visit isolagen.



Isolagen Forward Looking Statements



All statements in this news release that are not based on historical
fact are "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995 and the provisions of Section 27A
of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking statements in
this press release, include, without limitation, the timely completion of
the overall acne study, the timely completion of the Company's Phase III
wrinkle study, and the Company's ability to raise additional funding,
whether through strategic partners, financing, or otherwise. While
management has based any forward-looking statements contained herein on its
current expectations, the information on which such expectations were based
may change. These forward-looking statements rely on a number of
assumptions concerning future events and are subject to a number of risks,
uncertainties, and other factors, many of which are outside of our control,
that could cause actual results to materially differ from such statements.
Such risks, uncertainties, and other factors include, but are not
necessarily limited to, those set forth under Item 1A "Risk Factors" in the
Company's Annual Report on Form 10-K for the year ended December 31, 2007,
as updated in "Item 1A. Risk Factors" in the Company's Quarterly Reports on
Form 10-Q filed since the annual report. We operate in a highly competitive
and rapidly changing environment, thus new or unforeseen risks may arise.
Accordingly, investors should not place any reliance on forward-looking
statements as a prediction of actual results. We disclaim any intention to,
and undertake no obligation to, update or revise any forward-looking
statements. Readers are also urged to carefully review and consider the
other various disclosures in the Company's Annual Report on Form 10-K for
the year ended December 31, 2007, as well as other public filings with the
SEC since such date.


Isolagen, Inc.

isolagen